search
Back to results

Sexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'Ivoire (ANRS 12381)

Primary Purpose

HIV Infections, Viral Hepatitis B, Sexually Transmitted Diseases

Status
Recruiting
Phase
Not Applicable
Locations
Côte D'Ivoire
Study Type
Interventional
Intervention
Comprehensive package of sexual and reproductive health services
Sponsored by
ANRS, Emerging Infectious Diseases
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Infections focused on measuring female sex workers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Being a woman over 18 years of age
  • Self-reporting as being a sex worker
  • Wishing to enrol in a regular clinical follow-up
  • Agreeing to participate in the study and signing the informed consent form
  • Regardless of HIV status (infected or not)
  • Whether or not the participant has already taken antiretrovirals
  • Whether or not the participant is already followed by Aprosam

Exclusion Criteria:

  • Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or Sexually Transmitted Infections

Sites / Locations

  • AprosamRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention arm

Arm Description

Outcomes

Primary Outcome Measures

Completion rate of quarterly visits
Proportion of completed study visits
Proportion with at least one diagnosed STI
Occurrence of an unwanted pregnancy in the last 12 months
Initiation of PrEP
Among those eligible for PrEP, proportion having initiating PrEP
Adherence to PrEP
among those on PrEP, proportion being adherent (measured through self-report, pill count and drug detection in plasma)
Number of participants in HIV care at 18 months (retention)
Among those HIV-infected at baseline
Occurrence of virological failure
Among those HIV-infected and having initiated antiretroviral treatment, proportion with two consecutive detectable viral loads
HBV vaccination rate
among those needing hepatitis B vaccination, proportion with complete vaccination (3 doses if HIV-negative, 8 doses if HIV-positive) at the end of the trial
Initiation and number of participants on TDF (retention) for patients with a treatment for HBV mono-infection
among those with positive HBs-antigen and a F3-F4 fibrosis
Proportion with increase in transaminase level (flares) after PrEP discontinuation
Among those who started and stopped PrEP and with a positive HBs antigen
Number of adverse social events occurring in the daily life of participants
Assessment of adverse social events occurring in the daily life of participants
Composition of the vaginal microbiota
Percentage of cervical lesions at M0 and M12
Percentage of HPV infection and distribution of subtypes
Percentage of resistant bacterial STIs
Percentage of M.genitalium infections with mutations resistant to macrolide and fluoroquinolone at M0 and M12 Percentage of N.gonorrhoeae infections with resistance genes resistant to fluoroquinolone, ceftriaxone and cyclin at M0 and M12
Percentage of acceptability of different forms of long-acting PrEP for different sex workers profiles
Percentage of acceptability will be measured with in-depth individual interviews conducted with sex workers using a semi-structured interview guide including a biographical grid

Secondary Outcome Measures

Full Information

First Posted
March 13, 2019
Last Updated
June 2, 2022
Sponsor
ANRS, Emerging Infectious Diseases
Collaborators
Programme PAC-CI, Aprosam, San Pedro, Institut de Recherche pour le Developpement
search

1. Study Identification

Unique Protocol Identification Number
NCT03985085
Brief Title
Sexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'Ivoire
Acronym
ANRS 12381
Official Title
PrEP, Sexually Transmitted Infections, Contraception, Hepatitis B Virus, and Sexual Health for Female Sex Workers in Côte d'Ivoire
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 26, 2019 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ANRS, Emerging Infectious Diseases
Collaborators
Programme PAC-CI, Aprosam, San Pedro, Institut de Recherche pour le Developpement

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The PRINCESSE study will implement a comprehensive package of services in sexual and reproductive health for female sex workers in the region of San Pedro in Cote d'Ivoire, including screening, prevention and treatment for HIV, viral hepatitis B, sexually transmitted infections and family planning. All services will be available in mobiles clinics operating on prostitution sites and organized for a chronic follow-up of participants.
Detailed Description
PRINCESSE is a single-arm interventional cohort of 500 female sex workers (FSWs) in San Pedro, Cote d'Ivoire (400 HIV-negative FSW and 100 HIV-positive FSW). It consists in the implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction. This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant. The main objective is to develop, document and analyze a community-based healthcare package combining testing, prevention tools including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of Hepatitis B virus and sexual and reproductive health (SRH) Specific objectives are: To analyse access to care and retention into care, and more generally female participants' healthcare trajectories through a quarterly follow-up of FSWs (infected with HIV or not) To measure female participants' health outcome over time of clinical, behavioural and social indicators To assess PrEP initiation, use and adherence To compare HIV management in the PRINCESSE system with the existing routine treatment and care To measure HBV testing, vaccination and treatment, as part of a decentralised management integrated with HIV PrEP, and possible interactions between HIV PrEP and HBV infection To document the unexpected consequences (positive or negative) of PRINCESSE system on the everyday life of female participants in particular, and on the sex industry in general To evaluate the impact of vaginal microbiota on bacterial sexually transmitted infections, human papillomavirus (HPV) infections and associated cervical lesions; the impact of the HPV type distribution on the vaccinal strategy and the added value of HPV PCR for the primary screening of cervical cancer; and the impact of antimicrobial resistance on the STI guidelines. Assess the a priori acceptability and appropriateness of different forms of long-acting PrEP for different sex workers profiles. Four data collection devices are included in the cohort: (i) clinical and safety data, (ii) socio-behavioural questionnaires, (iii) biological data, and (iv) in-depth interviews with female participants. Eight additional data collections are scheduled outside the cohort itself: (i) capture of medical and activity records of Aprosam for PRINCESSE participants; (ii) capture of medical records of HIV+ FSW patients not participating in the PRINCESSE cohort and routinely examined by the NGO partner; (iii) in-depth interviews with key informants in the FSW community; (iv) in-depth interviews with PRINCESSE follow-up actors (peer educators and caregivers) (v) individual biographical interviews with female sex workers recruited by Aprosam and Espace Confiance about long-acting PrEP, supplemented by (vi) focus group discussions with female sex workers; (vii) focus group discussions with sex workers assigned men at birth; (viii) individual interviews with community actors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections, Viral Hepatitis B, Sexually Transmitted Diseases, Contraception
Keywords
female sex workers

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Comprehensive package of sexual and reproductive health services
Intervention Description
Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction. This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant.
Primary Outcome Measure Information:
Title
Completion rate of quarterly visits
Description
Proportion of completed study visits
Time Frame
up to 24 months
Title
Proportion with at least one diagnosed STI
Time Frame
up to 24 months
Title
Occurrence of an unwanted pregnancy in the last 12 months
Time Frame
up to 24 months
Title
Initiation of PrEP
Description
Among those eligible for PrEP, proportion having initiating PrEP
Time Frame
over 24 months
Title
Adherence to PrEP
Description
among those on PrEP, proportion being adherent (measured through self-report, pill count and drug detection in plasma)
Time Frame
up to 24 months
Title
Number of participants in HIV care at 18 months (retention)
Description
Among those HIV-infected at baseline
Time Frame
18 months
Title
Occurrence of virological failure
Description
Among those HIV-infected and having initiated antiretroviral treatment, proportion with two consecutive detectable viral loads
Time Frame
over 24 months (survival analysis)
Title
HBV vaccination rate
Description
among those needing hepatitis B vaccination, proportion with complete vaccination (3 doses if HIV-negative, 8 doses if HIV-positive) at the end of the trial
Time Frame
over 24 months
Title
Initiation and number of participants on TDF (retention) for patients with a treatment for HBV mono-infection
Description
among those with positive HBs-antigen and a F3-F4 fibrosis
Time Frame
over 24 months
Title
Proportion with increase in transaminase level (flares) after PrEP discontinuation
Description
Among those who started and stopped PrEP and with a positive HBs antigen
Time Frame
within 12 months after PrEP discontinuation
Title
Number of adverse social events occurring in the daily life of participants
Description
Assessment of adverse social events occurring in the daily life of participants
Time Frame
over 24 months
Title
Composition of the vaginal microbiota
Description
Percentage of cervical lesions at M0 and M12
Time Frame
up to 12 months
Title
Percentage of HPV infection and distribution of subtypes
Time Frame
up to 12 months
Title
Percentage of resistant bacterial STIs
Description
Percentage of M.genitalium infections with mutations resistant to macrolide and fluoroquinolone at M0 and M12 Percentage of N.gonorrhoeae infections with resistance genes resistant to fluoroquinolone, ceftriaxone and cyclin at M0 and M12
Time Frame
up to 12 months
Title
Percentage of acceptability of different forms of long-acting PrEP for different sex workers profiles
Description
Percentage of acceptability will be measured with in-depth individual interviews conducted with sex workers using a semi-structured interview guide including a biographical grid
Time Frame
over 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Being a woman over 18 years of age Self-reporting as being a sex worker Wishing to enrol in a regular clinical follow-up Agreeing to participate in the study and signing the informed consent form Regardless of HIV status (infected or not) Whether or not the participant has already taken antiretrovirals Whether or not the participant is already followed by Aprosam Exclusion Criteria: Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or Sexually Transmitted Infections
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Marie Masumbuko
Phone
+225 21755960
Email
masumbukojm@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Marcellin Nouanman
Phone
+225 21755960
Email
nouaman_et_vie@yahoo.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Larmarange, PhD
Organizational Affiliation
Institut de Recherche pour le Développement (IRD)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sege Eholié, MD PhD
Organizational Affiliation
Programme PAC-CI
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aprosam
City
San Pedro
Country
Côte D'Ivoire
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clémence Zebago, MD
Phone
+225 34000289
Email
zebsonclear@yahoo.fr
First Name & Middle Initial & Last Name & Degree
Aline Agoua, MD
Phone
+225 34000289
Email
alineasserayagoua@gmail.com
First Name & Middle Initial & Last Name & Degree
Clémence Zebago, MD
First Name & Middle Initial & Last Name & Degree
Aline Agoua, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The detailed IPD will be developed in the first year of project implementation to determine exact data that will be shared.
IPD Sharing Time Frame
within 24 months after trial's end
Citations:
PubMed Identifier
34863122
Citation
Becquet V, Nouaman M, Plazy M, Agoua A, Zebago C, Dao H, Montoyo A, Jary A, Coffie PA, Eholie S, Larmarange J; the ANRS 12381 PRINCESSE team. A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Cote d'Ivoire: the ANRS 12381 PRINCESSE project. BMC Public Health. 2021 Dec 4;21(1):2214. doi: 10.1186/s12889-021-12235-0.
Results Reference
derived

Learn more about this trial

Sexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'Ivoire

We'll reach out to this number within 24 hrs